Working... Menu

Geodon in Weight Loss Study for Bipolar Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00472641
Recruitment Status : Completed
First Posted : May 14, 2007
Results First Posted : May 9, 2017
Last Update Posted : May 9, 2017
Information provided by (Responsible Party):
Terrence Ketter, Stanford University

Brief Summary:
This research study is designed to determine if replacing your current antipsychotic and/or mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to be an effective medication for overweight or obese patients with bipolar disorder. There will be approximately 25 patients enrolled in this study.

Condition or disease Intervention/treatment Phase
Bipolar Disorder Drug: Ziprasidone/Geodon Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder
Study Start Date : January 2007
Actual Primary Completion Date : December 2009
Actual Study Completion Date : December 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Ziprasidone/Geodon
Ziprasidone/Geodon up to 320 mg per day
Drug: Ziprasidone/Geodon

Primary Outcome Measures :
  1. The Primary Outcome Measure Was Weight Change From Baseline to Endpoint. [ Time Frame: Baseline, 12 weeks ]
    The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.

Secondary Outcome Measures :
  1. Changes From Baseline to Endpoint in Body Mass Index (BMI) [ Time Frame: Baseline, 12 weeks ]
    Secondary outcome measures will include the change from baseline to endpoint in Body Mass Index (BMI).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:Patients will meet the following criteria to be eligible to participate in the study:

  • Diagnosis of Bipolar Disorder Type I, Type II, or NOS treated in ongoing therapy with atypical antipsychotic(s) and/or mood stabilizer(s) that have been implicated in causing weight gain (i.e. lithium, valproate, olanzapine, risperidone, quetiapine, aripiprazole).
  • Age 18-65 years old
  • Males; or nonpregnant, nonlactating females who are postmenopausal, surgically sterilized, or using a barrier method of contraception and have a negative pregnancy test
  • Initial body mass index e 30 kg/m2, or e 27 kg/m2 and demonstrating or receiving treatment for metabolic consequences of overweight (fasting total cholesterol e 200mg/dL, fasting triglycerides e 250 mg/dL, or fasting blood glucose e 100 mg/dL).
  • Stable medication regimen of at least one month
  • Not have been hospitalized due to medical or psychiatric reasons during the past year from date of consent.
  • Ability to understand and cooperate with study procedures
  • Have signed a written informed consent prior to entering the study Exclusion Criteria:Patients may not participate in the study if they have any of the following conditions:
  • One of the following DSM-IV Axis I diagnoses: delirium, dementia, amnestic and other cognitive disorders, schizophrenia, anorexia nervosa or bulimia, or substance abuse or dependence (active within the last month), abuse of illicit drugs (excluding marijuana) within the past month
  • Antisocial personality disorder
  • Medical complications of obesity such as diabetes, hypertension, hyperlipidemia, and cardiovascular disease unless followed by their own general medical practitioner who authorizes their participation in the trial, and continues to follow them medically and make necessary adjustments of concurrent antidiabetic, antihypertensive, antihyperlipidemic agents during the trial;
  • Item 10 (Suicidal Thoughts) on the MADRS greater than or equal to 4
  • Suicide attempt within the past three months
  • Obesity of endocrine origin
  • Seizure disorders
  • Progressive neurologic or systemic disorders; HIV
  • Other serious illnesses such as cardiac, hepatic (including cirrhosis), renal, respiratory, neurologic, or hematologic disease or glaucoma
  • Hypothyroidism or hyperthyroidism unless adequately treated with TSH no more than 10% above or below the limits of the normal range.
  • Administration of any investigational drug within 30 days prior to screening
  • Allergy or hypersensitivity to ziprasidone
  • Administration of clozapine in the prior three months
  • Pregnancy within the past six months
  • Patients will be discontinued from the study should they develop any significant adverse side effects that cannot be managed by dosage adjustment

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00472641

Layout table for location information
United States, California
Stanford University School of Medicine
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Layout table for investigator information
Principal Investigator: Terence Arthur Ketter Stanford University

Additional Information:
Layout table for additonal information
Responsible Party: Terrence Ketter, Professor, Stanford University Identifier: NCT00472641     History of Changes
Other Study ID Numbers: 96972
First Posted: May 14, 2007    Key Record Dates
Results First Posted: May 9, 2017
Last Update Posted: May 9, 2017
Last Verified: March 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Bipolar Disorder
Pathologic Processes
Bipolar and Related Disorders
Mental Disorders
Serotonin Antagonists
Serotonin Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists
Dopamine Agents